[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 136 pages | ID: E7F91B89E090EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 11, 2, 2, 13, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Epidermolysis Bullosa - Drug Profiles
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Jul 26, 2022: InMed enrols first adolescent in Phase II epidermolysis bullosa trial
Jun 22, 2022: Krystal Biotech submits biologics license application to U.S. FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa
May 23, 2022: Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data
May 19, 2022: Krystal Biotech to present additional data on B-VEC from the GEM-3 Phase 3 study at the Society for Investigative Dermatology Annual Meeting
May 18, 2022: Tetra Bio-Pharma receives EMA Orphan Drug Designation for a novel topical therapeutic containing CBD
Apr 11, 2022: Krystal Biotech announces home dosing in B-VEC open label extension study
Mar 28, 2022: Krystal Biotech announces publication of phase 1 and 2 clinical trial (GEM 1/2 Study) of beremagene geperpavec (B-VEC) data in Nature Medicine
Mar 26, 2022: New GEM-3 phase 3 results for B-VEC presented at 2022 American Academy of Dermatology Annual Meeting
Mar 18, 2022: Krystal Biotech to present at 2022 American Academy of Dermatology annual meeting
Mar 14, 2022: Abeona Therapeutics achieves target enrollment in pivotal phase 3 VIITAL study of EB-101 in RDEB
Nov 30, 2021: Krystal’s dystrophic EB gene therapy trial meets primary goal
Nov 18, 2021: Abeona Therapeutics announces support of EB research partnership's venture into cures event to raise awareness for education and research of epidermolysis bullosa
Oct 26, 2021: Krystal Biotech announces completion of the GEM-3 pivotal phase 3 study evaluating B-VEC for the treatment of dystrophic epidermolysis bullosa
Oct 21, 2021: Castle Creek Biosciences awarded FDA Orphan products development grant to support DeFi-RDEB, a pivotal phase 3 study of FCX-007 investigational gene therapy for recessive dystrophic epidermolysis bullosa
Sep 30, 2021: InMed Pharmaceuticals announces commencement of phase 2 clinical trial investigating cannabinol (CBN), a rare cannabinoid, in the treatment of epidermolysis bullosa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Epidermolysis Bullosa, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, 2022
Epidermolysis Bullosa - Pipeline by Almirall SA, 2022
Epidermolysis Bullosa - Pipeline by Amniotics AB, 2022
Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, 2022
Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Avicanna Inc, 2022
Epidermolysis Bullosa - Pipeline by Berg LLC, 2022
Epidermolysis Bullosa - Pipeline by Biomendics LLC, 2022
Epidermolysis Bullosa - Pipeline by Branca Bunus Ltd, 2022
Epidermolysis Bullosa - Pipeline by Carocell Bio Ltd, 2022
Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, 2022
Epidermolysis Bullosa - Pipeline by Celularity Inc, 2022
Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, 2022
Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, 2022
Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Energenesis Biomedical Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, 2022
Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate SRL, 2022
Epidermolysis Bullosa - Pipeline by Immusoft Corp, 2022
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Kangstem Biotech Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, 2022
Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, 2022
Epidermolysis Bullosa - Pipeline by Mariposa Therapeutics Ltd, 2022
Epidermolysis Bullosa - Pipeline by Onconova Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by OTR3 SAS, 2022
Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, 2022
Epidermolysis Bullosa - Pipeline by Panag Pharma Inc, 2022
Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, 2022
Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, 2022
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Relief Therapeutics Holding AG, 2022
Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, 2022
Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by StemRIM Inc, 2022
Epidermolysis Bullosa - Pipeline by Therapicon Srl, 2022
Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, 2022
Epidermolysis Bullosa - Pipeline by Vera Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by Wings Therapeutics, 2022
Epidermolysis Bullosa - Dormant Projects, 2022
Epidermolysis Bullosa - Dormant Projects, 2022 (Contd..1)
Epidermolysis Bullosa - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Epidermolysis Bullosa, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications